GRAIL, Inc. (GRAL), a biotechnology firm focused on blood-based cancer screening technology, experienced a setback for early multi-cancer detection when its Galleri test did not achieve the primary endpoint in a large-scale UK National Health Service study. The company reported selling 185,000 tests in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments